Tyra Biosciences (NASDAQ:TYRA) Price Target Raised to $43.00 at Jefferies Financial Group

Tyra Biosciences (NASDAQ:TYRA) had its price target hoisted by Jefferies Financial Group from $32.00 to $43.00 in a research report sent to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Barclays assumed coverage on Tyra Biosciences in a report on Tuesday, January 27th. They set an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Wednesday, January 21st. Piper Sandler increased their price target on Tyra Biosciences from $33.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, January 23rd. Finally, Wedbush raised their price target on Tyra Biosciences from $30.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.17.

Tyra Biosciences Price Performance

Shares of NASDAQ TYRA opened at $31.24 on Tuesday. The business has a fifty day moving average price of $26.32 and a 200 day moving average price of $17.89. Tyra Biosciences has a 1-year low of $6.42 and a 1-year high of $32.44. The stock has a market capitalization of $1.67 billion, a P/E ratio of -16.71 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). As a group, equities research analysts anticipate that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Robert J. More sold 10,000 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the transaction, the director directly owned 3,823,425 shares of the company’s stock, valued at approximately $95,585,625. This represents a 0.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 15.20% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently bought and sold shares of TYRA. Chung Wu Investment Group LLC purchased a new stake in shares of Tyra Biosciences in the 4th quarter valued at $53,000. Federated Hermes Inc. lifted its position in Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock valued at $30,000 after purchasing an additional 1,841 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Tyra Biosciences by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after purchasing an additional 534 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the 3rd quarter worth about $133,000. Finally, Russell Investments Group Ltd. raised its stake in shares of Tyra Biosciences by 27.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock valued at $178,000 after buying an additional 2,766 shares during the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.